DrugPatentWatch Database Preview

Drugs in Development Information for RDEA3170

Email this page to a colleague

« Back to Dashboard

What is the drug development status for RDEA3170?

RDEA3170 is an investigational drug.

There have been 15 clinical trials for RDEA3170. The most recent clinical trial was a Phase 2 trial, which was initiated on May 28^th 2017.

The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and PAREXEL Early Phase Clinical Unit Baltimore.

There are fourteen US patents protecting this investigational drug and one hundred and eighty-nine international patents.

Summary for RDEA3170

US Patents	14
International Patents	189
US Patent Applications	28
WIPO Patent Applications	19
Japanese Patent Applications	8
Clinical Trial Progress	Phase 2 (2017-05-28)
Vendors	27

Recent Clinical Trials for RDEA3170

Title	Sponsor	Phase
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Analytical Laboratory (Pharmacokinetic Sample Analysis): USA	Phase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Clinical Laboratory: USA	Phase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	Contract Research Organization: USA	Phase 2

See all RDEA3170 clinical trials

Clinical Trial Summary for RDEA3170

Top disease conditions for RDEA3170

Top clinical trial sponsors for RDEA3170

See all RDEA3170 clinical trials

US Patents for RDEA3170

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
RDEA3170		3,4-di-substituted pyridine compound, methods of using and compositions comprising the same	ARDEA BIOSCIENCES, INC. (San Diego, CA)
RDEA3170		Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof	SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN)
RDEA3170		Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof	SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN)
RDEA3170		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
RDEA3170		URAT1 inhibitor	Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP)

International Patents for RDEA3170

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
RDEA3170	Australia	AU2012332154	2031-11-03
RDEA3170	Brazil	BR112014010495	2031-11-03
RDEA3170	Canada	CA2852490	2031-11-03
RDEA3170	China	CN104023723	2031-11-03
RDEA3170	China	CN106963761	2031-11-03